Articles tagged with Sjogrens Syndrome
A study reveals that a cellular interaction between immune cells and fibroblasts drives the progression of Sjögren's disease by promoting chronic inflammation. The CD153+ CD4+ T cell-CD30+ fibroblast axis is identified as a key trigger, and targeting this axis may provide new therapeutic opportunities.
Scientists discover autoimmune vicious cycle in Sjögren's disease, where CD4+ T cells recognize Ro60 protein and sustain antibody production. This process forms a self-reinforcing loop, contributing to chronic disease, and could lead to targeted therapies with fewer side effects.
Researchers have found a widely available drug combination to be an effective treatment for patients with systemically active Sjögren's disease. The combination of leflunomide and hydroxychloroquine reduced disease activity while maintaining a favorable safety profile.
Researchers mapped over 1.25 million cells to reveal sex-specific differences in the human immune system. Female immune cells exhibit higher levels of B cells and regulatory T cells, but also a greater predisposition to autoimmune diseases like lupus due to their highly reactive profile.
A study of 371 patients with autoimmune hepatitis (AIH) found that extrahepatic autoimmune diseases (EADs) are common, particularly Sjogren's syndrome and autoimmune thyroid disease. Patients with EADs had a poorer early treatment response but achieved comparable outcomes after six months.
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
Researchers at KAIST have identified a critical protein called SLIRP that acts as an 'immune switch' regulating immune responses to viruses and autoimmune diseases. Suppressing SLIRP can alleviate abnormal immune responses in patients with Sjögren's syndrome, coronavirus, and encephalomyocarditis virus infection.
A study published in Lancet eClinical Health found pregnancy outcomes for pregnant individuals with autoimmune disease vary greatly depending on the specific condition and individual factors. Research highlights the importance of considering comorbidities when discussing autoimmune disease and pregnancy.
A large-scale review of anti-inflammatory drugs used for autoimmune disorders suggests that current treatments can worsen lipid metabolism, leading to increased cardiovascular disease risk. Researchers propose the development of combination therapies targeting lipid metabolism to reduce immune complications and CVD risk in patients.
Research found that complement gene variants contribute to sex-based differences in vulnerability to autoimmune diseases lupus and Sjögren's syndrome, as well as mental disorder schizophrenia. Complement protein levels vary between men and women, with different age-related elevations and effects on disease incidence.
A new study has discovered four subtypes of primary Sjögren's syndrome, a chronic inflammatory disease affecting the body's fluid production. This finding offers hope for personalized treatment and improved quality of life for patients.
A study of 9,048 individuals in Sweden found that respiratory, skin, and urogenital infections significantly increase the risk of developing Sjögren's syndrome. The findings support the hypothesis that environmental triggers play a crucial role in its development.
Researchers at the Forsyth Institute have defined the immune-regulatory mechanisms of Sjögren's syndrome, revealing how PD-L1 and PD-1 proteins interact to suppress protective immunity. The study found that inhibiting this pathway accelerates autoimmune responses and disease development.
A new study led by University at Buffalo researcher Jill Kramer aims to re-examine the role of IgM in Sjögren's syndrome. The research seeks to understand whether this protective antibody is also pathogenic, potentially leading to a better understanding of autoimmune diseases.
Women with primary Sjögren's syndrome experience impaired sexual functioning and higher levels of distress compared to healthy controls. Vaginal dryness, pain, fatigue, and depressive symptoms significantly contribute to their symptoms. Healthcare providers should acknowledge and discuss these issues to help patients cope.
A recent study published in JAMA found that hydroxychloroquine, a commonly prescribed treatment for primary Sjögren syndrome, did not improve symptoms in patients. The 24-week trial involved 120 patients and showed no significant difference between hydroxychloroquine and placebo groups.
A study found that Sjögren's Syndrome significantly increases the risk of heart attack in patients, particularly within the first year following diagnosis. The research highlights the importance of active management of cardiovascular risk factors to reduce the risk of a future heart attack.
Patients with Sjögren's syndrome report higher levels of cognitive, psychological, and physical impairment than peers, yet still maintain high functional levels. The study suggests that people with Sjögren's can compensate for the disease's effects and function reasonably well.
Researchers found autoantibodies in patients with primary Sjögren syndrome 18-7 years before symptoms appeared. The study's results suggest that autoantibody profiling may help identify individuals at risk of autoimmune disease years before symptom onset.
Researchers have identified six new disease-related genes for Sjögren's syndrome, an autoimmune disease that affects moisture-producing glands. The findings provide a first step towards understanding how genetic variants alter immune system functions and may lead to the development of therapeutics.
The American Association for Dental Research awarded Page Linae Collymore a $4,000 student fellowship to encourage research on Sjögren's Syndrome. She is a student at Southern Illinois University and will be recognized at the AADR's 41st Annual Meeting in March 2012.
A study found that patients with Sjögren's syndrome are more likely to experience difficulty identifying and describing emotions (alexithymia), which is associated with poorer mental wellbeing. The inability to cry may also contribute to this issue, as patients rely on words and facial expressions instead of tears.
Researchers validated three salivary mRNA biomarkers (B2M, GIP2, MNDA) and three protein biomarkers (B2M, SSA, SSB) for detecting Sjogren's syndrome in the US population, expanding clinical utility of existing biomarkers.
Dr. Hui Shao has received a grant from the Research to Prevent Blindness organization to study Sjogren's syndrome, a chronic autoimmune disease affecting millions of Americans. Her team has discovered a protein called Klk22, which may play a role in the development of the disease.
Researchers found that green tea's EGCG reduced salivary gland damage and delayed insulin-dependent type 1 diabetes in a laboratory mouse. The study also showed that EGCG suppressed abnormal gene expression and lowered serum autoantibodies, reducing Sjogren's syndrome-like symptoms.
Researchers found significantly less salivary gland damage in a group treated with green tea extract, suggesting a reduction of Sjogren's Syndrome symptoms like dry mouth. Green tea's EGCG component may also suppress inflammation and turn on the body's defense system against TNF-alpha.
Researchers developed a genetically altered mouse model for Sjögren's syndrome, a rare autoimmune disorder affecting 0.6 percent of the population. The Id3-deficient mice exhibited reduced tear and saliva secretion, lymphocyte infiltration, and autoantibody production, mirroring human disease characteristics.
A team of researchers at the University of Toronto has identified a protein and developed a prototype vaccine that shows promise in treating Sjögren syndrome. The vaccine was able to stop disease progression even after the condition had fully developed.